A Viable Neuroprotection Strategy Following Soman-induced Status Epilepticus
Abstract
The present study examined the neuroprotective effectiveness of dantrolene in the prevention of soman-induced SRBD. (Dantrolene is FDA approved for the treatment of malignant hyperthermia.) The decision to consider this compound is based on its well-known mode of action in preventing the release of calcium from intracellular stores. In addition, we assessed possible synergistic overlap in the neuroprotective effectiveness of combined dantrolene and diazepam co-treatment. The combined neuroprotective effectiveness of diazepam+dantrolene is compared with that of diazepam+HU-211 (dexanabinol). The present results provide strong evidence that, by blocking the release of calcium from intracellular stores, dantrolene synergistically augmented the neuroprotection produced by diazepam alone.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2003
- Accession Number
- ADA443565
Entities
People
- G. P. Ballough
- M. G. Filbert
Organizations
- United States Army Medical Research Institute of Chemical Defense